AgeneBio to study AGB101 in Phase III trial to treat MCI due to AD

US-based pharmaceutical firm AgeneBio is set to investigate its therapeutic agent AGB101 in a Phase III clinical trial (HOPE4MCI) for the treatment of mild cognitive impairment due to Alzheimer ’s disease (MCI due to AD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news